BTK Inhibitors: In-Focus

Continued data for the first-generation BTK inhibitor have demonstrated its expanding utility amid a growing treatment arsenal.

With the treatment landscape rapidly developing with the approval of new agents and the investigation of various combination regimens, understanding the individual profiles of each agent will aid treatment selection.

Findings suggest that combination regimens may extend overall and progression-free survival.

Targeting different pathways may dramatically reduce the risk of resistance emergence and improve outcomes.

Paul M. Barr, MD discusses key takeaways from the follow-up data and reflects on the clinical and practical implications of the 7-year findings.

Zanubrutinib has demonstrated clinical benefit as both a monotherapy and in combination with other agents for the treatment of patients with chronic lymphocytic leukemia.